Kisspeptin (10 mg vial)

Protocol Overview

Concise summary of the regimen.

Dosing & Reconstitution

Frequency: Inject once daily subcutaneously. This schedule follows a conservative titration to assess individual response. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 1 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl until dissolved (do not shake).
4. Label and refrigerate at 2 to 8 °C, protected from light. At 10 mg/mL, 1 unit = 0.01 mL » 100 mcg on a U-100 insulin syringe.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: store at -20 °C in dry, dark conditions with desiccant if possible.
• Reconstituted: refrigerate at 2 to 8 °C; stable up to ~4 weeks; avoid freeze-thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Supplies Needed

Plan based on an 8 to 16 week daily protocol with gradual titration.

Peptide Vials (Kisspeptin, 10 mg each):

• 8 weeks: ~1 vial. 12 weeks: ~2 vials. 16 weeks: ~3 vials.

Insulin Syringes (U-100):

• Per week: 7 syringes (1/day).
• 8 weeks: 56. 12 weeks: 84. 16 weeks: 112.

Bacteriostatic Water (10 mL bottles):

• 8 to 16 weeks (1 to 3 vials): 1 bottle.

Alcohol Swabs:

• Per week: 14 swabs.
• 8 weeks: 112 (2 x 100-count). 16 weeks: 224 (3 x 100-count).

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation.
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• Discard bacteriostatic water after 28 days once opened.

How This Works

Kisspeptin is an upstream trigger for the reproductive hormone cascade. Upon subcutaneous injection, kisspeptin rapidly binds to kisspeptin receptors (GPR54) on GnRH neurons in the hypothalamus, causing immediate release of GnRH. This in turn stimulates the anterior pituitary to secrete LH and FSH, which act on the gonads to boost sex steroid production and support gametogenesis. Importantly, kisspeptin's action is GnRH-dependent: if GnRH release is blocked, kisspeptin cannot induce LH/FSH secretion. This confirms that kisspeptin works by unlocking the body's own GnRH stores, providing a more physiologic pattern of hormone release compared to direct GnRH or hCG administration.

Benefits & Side Effects

Observations from preclinical and clinical literature.

• Physiological sex hormone stimulation: increases endogenous testosterone and estrogen levels by

amplifying the body's own LH/FSH signals without suppressing the HPG axis.

• Fertility restoration: shows promise in functional hypothalamic amenorrhea by rekindling GnRH/LH

pulsatility and resuming menstrual cycles.

• IVF ovulation trigger: can induce robust LH surge to mature oocytes while potentially lowering the risk

of ovarian hyperstimulation syndrome compared to traditional hCG triggers.

• Safety profile: generally well tolerated; occasional mild injection-site reactions (redness, itch) may occur

with subcutaneous administration.

Lifestyle Factors

Complementary strategies for best outcomes.

• Maintain adequate nutrition and healthy body weight to support endogenous hormone production.
• Prioritize sleep and stress management, as these factors significantly impact the HPG axis.
• Monitor for changes in reproductive function or hormone-related symptoms.
• Consider combining with appropriate lifestyle interventions for conditions of hypothalamic suppression.

Injection Technique

General subcutaneous guidance from clinical best-practice resources.

1. Clean the vial stopper and skin with alcohol; allow to dry.
2. Pinch a skinfold; insert the needle at 45 to 90 degrees into subcutaneous tissue.
3. Do not aspirate for subcutaneous injections; inject slowly and steadily.
4. Wait 5 to 10 seconds before withdrawing; dispose of syringe in sharps container.
5. Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.

References

Source citations for further reading.

1. Emerging Therapeutic Potential of Kisspeptin and Neurokinin B (Endocrine Reviews).
2. Kisspeptin-54 triggers egg maturation in IVF with reduced OHSS risk (J Clinical Investigation).
3. Functional hypothalamic amenorrhea: restoration of GnRH pulsatility (Endocrine Reviews).
4. Kisspeptin mechanism: GPR54 receptor binding and GnRH release (Endocrine Reviews).